tm logo
ZUVYZMA
Live/Pending
FIRST EXTENSION - GRANTED

granted

on 20 Mar 2024

Last Applicant/ Owned by

One Johnson & Johnson Plaza

New Brunswick

NJ

08933

Serial Number

97463283 filed on 17th Jun 2022

Registration Number

N/A

Correspondent Address

Cheryl L. Foytlin

JOHNSON & JOHNSON

ONE JOHNSON & JOHNSON PLAZA

NEW BRUNSWICK,NJ 08933

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

ZUVYZMA

The wording "ZUVYZMA" has no meaning in a foreign language. Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, pulmonary diseases, cardiovascular diseases, central nervous system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, cerebrovasRead More

Classification Information


Class [005]
Pharmaceutical Products


Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, pulmonary diseases, cardiovascular diseases, central nervous system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, cerebrovascular diseases, ophthalmic diseases, and respiratory diseases; anti-allergics; vaccines

Mark Details


Serial Number

No 97463283

Mark Type

No Service/Collective Mark

Attorney Docket Number

No T46794US1

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
20th Mar 2024SOU TEAS EXTENSION RECEIVED
20th Mar 2024SOU EXTENSION 1 FILED
20th Mar 2024SOU EXTENSION 1 GRANTED
03rd Oct 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
08th Aug 2023PUBLISHED FOR OPPOSITION
08th Aug 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19th Jul 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29th Jun 2023APPROVED FOR PUB - PRINCIPAL REGISTER
31st May 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
31st May 2023CORRESPONDENCE RECEIVED IN LAW OFFICE